Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Gastric or Esophagogastric Junction Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (ruihua Xu) · xurh@sysucc.org.cn

Study leads

ruihua Xu, Doctor
Principal Investigator
Sun Yat-sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Hefei, China · Hefei, China

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Gastric Cancer Stage IV · Peritoneal Metastases From Gastric Cancer · Gastric or Esophagogastric Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer · Esophagogastric Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Adenocarcinoma · Stomach Neoplasm · Gastroesophageal-junction Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China